Počet záznamů: 1  

Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression

  1. 1.
    0452269 - ÚEM 2016 RIV GB eng J - Článek v odborném periodiku
    Aherne, S.T. - Madden, S.F. - Hughes, D. J. - Pardini, B. - Naccarati, A. - Levý, M. - Vodička, Pavel - Neary, P. - Dowling, P. - Clynes, M.
    Circulating miRNAs miR-34a and miR-150 associated with colorectal cancer progression.
    Bmc Cancer. Roč. 15, apr 30 (2015), s. 2-13. E-ISSN 1471-2407
    Grant CEP: GA ČR GAP304/10/1286
    Institucionální podpora: RVO:68378041
    Klíčová slova: colorectal cancer * circulating miRNAs * miR-34a * miR-150 * miR-923
    Kód oboru RIV: EB - Genetika a molekulární biologie
    Impakt faktor: 3.265, rok: 2015

    Background: Screening for the early detection of colorectal cancer is important to improve patient survival. The aim of this study was to investigate the potential of circulating cell-free miRNAs as biomarkers of CRC, and their efficiency at delineating patients with polyps and benign adenomas from normal and cancer patient groups. Methods: The expression of 667 miRNAs was assessed in a discovery set of 48 plasma samples comprising normal, polyp, adenoma, and early and advanced cancer samples. Three miRNAs (miR-34a, miR-150, and miR-923) were further examined in a validation cohort of 97 subjects divided into the same five groups, and in an independent public dataset of 40 CRC samples and paired normal tissues. Results: High levels of circulating miR-34a and low miR-150 levels distinguished groups of patients with polyps from those with advanced cancer (AUC = 0.904), and low circulating miR-150 levels separated patients with adenomas from those with advanced cancer (AUC = 0.875). In addition, the altered expression of miR-34a and miR-150 in an independent public dataset of forty CRC samples and paired normal tissues was confirmed. Conclusion: We identified two circulating miRNAs capable of distinguishing patient groups with different diseases of the colon from each other, and patients with advanced cancer from benign disease groups.
    Trvalý link: http://hdl.handle.net/11104/0253298

     
     
Počet záznamů: 1  

  Tyto stránky využívají soubory cookies, které usnadňují jejich prohlížení. Další informace o tom jak používáme cookies.